Novalis LifeSciences

Type

Venture Capital

Status

Active

Location

Portsmouth, United States

Total investments

22

Average round size

63M

Portfolio companies

16

Rounds per year

3.67

Lead investments

4

Follow on index

0.23

Exits

2

Areas of investment
BiotechnologyHealth CareHealth DiagnosticsMedical DeviceLife ScienceTherapeuticsAgTechService IndustryChemicalAgriculture

Investor highlights

Industry focus
Biotech/Life SciencesMedtech
Stage focus
Seed

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 300000000
Fund raised date
2021-12-08

Analytics

Total investments
22
Lead investments
4
Exits
2
Rounds per year
3.67
Follow on index
0.23
Investments by industry
  • Biotechnology (18)
  • Therapeutics (8)
  • Agriculture (5)
  • Health Care (5)
  • Medical Device (4)
  • Show 13 more
Investments by region
  • United States (16)
  • United Kingdom (1)
  • Belgium (3)
  • Netherlands (1)
Peak activity year
2022
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
7
Avg. valuation at time of investment
22M
Group Appearance index
0.95
Avg. company exit year
8

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
BlueWhale Bio 07 Sep 2023 Biotechnology, Manufacturing Seed 18M United States, Pennsylvania, Philadelphia
MysteryVibe 01 May 2018 Health Care, Wellness, Product Design, Personal Health, Toys Seed 2M United Kingdom, London, England
Vizgen 07 Apr 2021 Biotechnology Early Stage Venture 37M United States, Massachusetts, Cambridge
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.